The evaluation of the effect of intravenous Tranexamic acid in external DCR (Dacryocyctorhinostomy)

The evaluation of the effect of intravenous Tranexamic acid in reducing the amount of bleeding during external DCR (Dacryocyctorhinostomy) in patients with nasolacrimal duct obstruction ( NLDO) compared to control group

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211121053138N1

Enrollment

Registered

2021-12-01

Start date

2021-12-21

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasolacrimal duct obstruction. Stenosis and insufficientcy of lacrimal passages

Interventions

Intervention 1: Intervention group: Tranexamic acid will be injected intravenously only once, at a dose of 10 mg per kilo, half an hour before surgery. The manufacturer of the drug is CASPIAN TAMIN. I

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with nasolacrimal duct obstruction

Exclusion criteria

Exclusion criteria: Any history of trauma to lacrimal drainage system History of coagulopathy state History of bleeding disorders History of Covid-19 in the last 6 months

Design outcomes

Primary

Measure	Time frame
Record the amount of intraoperative bleeding at external dacryocyctorhinostomy. Timepoint: at the end of surgery. Method of measurement: The amount of bleeding recorded by a standard suction device in a calibrated tank.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamaneh Gholamhosseinpour-Omran

Mashhad University of Medical Sciences

gholamhoseinpoursamaneh@gmail.com+98 51 3844 0459

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026